A lot of investors missed the initial gold rush vis-a-vis the GLP-1 weight loss drugs in 2022/2023. Now, however, there is an opportunity to capture the second-order derivative tailwinds from these drugs by going long on stocks that are focused on cosmetic/aesthetic procedures, including Evolus (NASDAQ: EOLS), Inmode (NASDAQ: INMD), and AbbVie (NYSE: ABBV). A Primer on GLP-1 Weight Loss Drugs GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. A lot of these drugs currently on the market are in the injectable form. Novo Nordisk uses Semaglutide as its proprietary […]
Read full article at https://wccftech.com/glp-1-drugs-are-about-to-unleash-a-gold-rush-for-cosmetic-procedures-benefiting-evolus-eols-inmode-inmd-and-abbvie-abbv-shares/
